Results 31 to 40 of about 18,017 (247)

Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex

Haematologica, 2012
Background Hemophilia is caused by deficiencies in coagulation factor VIII or IX, resulting in direct blockade of the intrinsic tenase complex and indirect blockade of the extrinsic tenase complex which is rapidly inhibited upon binding of factor Xa to ...
Raphaël Marlu, Benoît Polack
doaj   +1 more source

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis

Frontiers in Cardiovascular Medicine, 2022
BackgroundNon-vitamin K antagonist oral anticoagulants (NOACs) showed a benefit-risk profile superior to that of warfarin in atrial fibrillation (AF) patients with mild to moderate chronic kidney disease. However, the effectiveness and safety of NOACs in
Wenhao Li, Yanxia Zhou, Siqi Chen, Dewang Zeng, Haidong Zhang   +4 more
doaj   +1 more source

Andexanet alfa - what we know about this promising drug

Journal of Education, Health and Sport, 2023
Introduction and purpose. Andexanet alfa (AA) is a recombinant modified version of human activated factor X. It is used as an antidote for apixsaban and rivaroxaban when reversal of anticoagulation due to life-threatening or uncontrolled bleeding is ...
Natalia Ilnicka, Patrycja Zuziak, Maria Sadlik, Daria Matyja, Leila Abod   +4 more
doaj   +1 more source

Reversal of Oral Anticoagulants: A Survey of Contemporary Practice Trends (ReACT)

Clinical and Applied Thrombosis/Hemostasis, 2023
This study evaluated practice patterns and factors influencing treatment decisions regarding urgent or emergent reversal of oral anticoagulants (OACs). A 30-question survey was electronically distributed to anticoagulation members of the Anticoagulation ...
Huiwen Deng PharmD, MPH, Edith A. Nutescu PharmD, MS CTS, FCCP, Robert J. DiDomenico PharmD, FCCP, FHFSA, FACC   +2 more
doaj   +1 more source

Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa

Molecules, 2020
Coagulation factor Xa and factor XIa are proven to be convenient and crucial protein targets for treatment for thrombotic disorders and thereby their inhibitors can serve as effective anticoagulant drugs.
Nadezhda Novichikhina, Ivan Ilin, Anna Tashchilova, Alexey Sulimov, Danil Kutov, Irina Ledenyova, Mikhail Krysin, Khidmet Shikhaliev, Anna Gantseva, Ekaterina Gantseva, Nadezhda Podoplelova, Vladimir Sulimov   +11 more
doaj   +1 more source

Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

TH Open, 2020
Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However, data from randomized trials may not extrapolate to general population. We aimed to
Yimin Pearl Wang, Rohan Kehar, Alla Iansavitchene, Alejandro Lazo-Langner   +3 more
doaj   +1 more source

Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients

PLoS ONE, 2022
Background Maintenance drugs are used to treat chronic conditions. Several classes of maintenance drugs have attracted attention because of their potential to affect susceptibility to and severity of COVID-19.
Kin Wah Fung, Seo H. Baik, Fitsum Baye, Zhaonian Zheng, Vojtech Huser, Clement J. McDonald   +5 more
doaj   +2 more sources

Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Important disparities in the treatment and outcomes of women and men with atrial fibrillation (AF) are well recognized. Whether introduction of direct oral anticoagulants has reduced disparities in treatment is uncertain.
Kuan Ken Lee, Dimitrios Doudesis, Rong Bing, Federica Astengo, Jesus R. Perez, Atul Anand, Shauna McIntyre, Nicholas Bloor, Belinda Sandler, Steven Lister, Kevin G. Pollock, Ayesha C. Qureshi, David A. McAllister, Anoop S. V. Shah, Nicholas L. Mills   +14 more
doaj   +1 more source

The new factor Xa inhibitor: Apixaban

Journal of Pharmacology and Pharmacotherapeutics, 2014
Cardiovascular diseases are still the most important cause of morbidity and mortality worldwide and anti-thrombotic treatment is widely used as a result. The currently used drugs include heparin and its derivatives, vitamin K antagonists, though efficacious, have their own set of limitations like unpredictable pharmacokinetic profile, parenteral route (
Bhanwra, Sangeeta, Ahluwalia, Kaza
openaire   +3 more sources

Rivaroxaban: A New Oral Factor Xa Inhibitor [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2010
Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway leading to thrombin generation and clot formation. It is selective for human factor Xa, for which it has >10 000-fold greater selectivity than for other biologically relevant serine proteases (half-maximal ...
Elisabeth, Perzborn, Susanne, Roehrig, Alexander, Straub, Dagmar, Kubitza, Wolfgang, Mueck, Volker, Laux   +5 more
openaire   +2 more sources